Institutional Review Board, Hospital for Special Surgery
October 06, 2016
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
Robert F. Spiera, MD
Systemic sclerosis (SSc) is a rare, often fatal disease with an unknown cause, which has no effective therapy. One of the most serious complications of systemic sclerosis is pulmonary hypertension (PHT), which is the most frequent cause of death from a scleroderma complication. New therapeutic advances have recently improved the short-term management of pulmonary hypertension in scleroderma, but the long-term outcomes are unknown.
This is a multicenter, longitudinal, prospective registry where we collect clinical and biological information on scleroderma patients with a high risk of developing pulmonary artery hypertension (PAH) or with recently diagnosed PAH. There are currently 5 enrolled patients. The study consist of a baseline visit and a 6 month follow up.
Patient > 18 years with a clinical diagnosis of SSc (ACR criteria or the LeRoy criteria for limited or diffuse scleroderma)
diagnosis of "pre" pulmonary arterial hypertension defined as:
Echocardiogram with a resting sPAP of >40mmHg
Pulmonary function test with FVC > 70% and a DLCO <55% of predicted or a FVC/DLCO ratio > 1.6
Patients entered as a 'pre'-pulmonary arterial hypertension who then undergo right heart catheterization and are found to have pulmonary artieral hypersion, pulmonary venous hypertension or diastolic dysfunction or pulmonary hypertension secondary to interstitial lung disease will be followed as a definite PH patient and classified into the appropriate category.
Diagnosis of definite pulmonary hypertension
Diagnosis and treatment of pulmonary hypertension for > 6 months
Patients with known severe interstitial fibrosis, pulmonary thrombotic disease, heart failure, cardiomyopathy, history of coronary artery disease or other cardio-pulmonary problems which could cause pulmonary hypertension are not eligible for the 'pre'-pulmonary hypertension group but do qualfy for the definite pulmonary hypertension group if they have a right heart catheterization showing a mean PAH of >25mmHg.